trending Market Intelligence /marketintelligence/en/news-insights/trending/At0vFFEJMGJsOZ7jTspfjQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Immunotec fiscal Q2 profit climbs YOY


ESG hits the mainstream for European private equity sponsors


What’s the Bottom Line: Credit Impact of COVID-19 on US Municipals


Banking Essentials Newsletter - February Edition, Part 2


Episode 3: Transformation of Customer Experience in 2020

Immunotec fiscal Q2 profit climbs YOY

Immunotec Inc. said its normalized net income for the fiscal second quarter ended April 30 came to C$633,090, a gain from C$267,070 in the prior-year period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin rose to 2.5% from 1.3% in the year-earlier period.

Total revenue climbed 28.1% on an annual basis to C$25.6 million from C$20.0 million, and total operating expenses climbed 26.9% on an annual basis to C$23.8 million from C$18.7 million.

Reported net income grew 61.9% year over year to C$559,280, or 1 cents per share, from C$345,510, or 0 cents per share.